Key Details
Price
$2.90PE Ratio
5.29Annual ROE
-49.27%Beta
1.09Events Calendar
Next earnings date:
Apr 24, 2025Recent quarterly earnings:
Nov 12, 2024Recent annual earnings:
Apr 24, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Investors need to pay close attention to CureVac (CVAC) stock based on the movements in the options market lately.
CureVac N.V. (NASDAQ:CVAC ) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ET Company Participants Sarah Fakih - Vice President of Corporate Communications and Investor Relations Alexander Zehnder - Chief Executive Officer Axel Malkomes - Chief Financial Officer Myriam Mendila - Chief Development Officer Rudiger Wolff - Senior Vice President of Finance Conference Call Participants Charlie Yang - Bank of America Merrill Lynch CJ Yeh - Leerink Partners Roy Buchanan - Citizens JMP Operator Greetings and welcome to the CureVac Financial Results and Business Update for the Third Quarter and First Nine Months of 2024 Conference Call.
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that new and updated data will be shared in two oral presentations and four posters at the 12th International mRNA Health Conference, taking place in Boston, Massachusetts, November 12-14, 2024.
First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBM Part B expected to include up to 20 patients to generate extended data on safety, tolerability, and immunogenicity of CVGBM TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the start of the dose-confirmation Part B of its ongoing Phase 1 study in patients with resected glioblastoma.
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today named clinical oncologist Mehdi Shahidi, M.D.
CureVac (CVAC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CureVac (CVAC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CureVac (NASDAQ: CVAC ) layoffs are coming for the vaccine maker's employees as it prepares to undergo a restructuring to streamline its business. CureVac has announced that its layoffs will affect 30% of its global workforce.
CureVac (NASDAQ: CVAC ) stock is on the rise Wednesday after the company announced a restructured licensing agreement with GSK (NYSE: GSK ). This new agreement has GSK taking over the development and manufacturing of certain vaccines made by CureVac.
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization Prioritization of high-value opportunities in oncology and other selected diseases, leveraging proprietary mRNA technology to develop novel treatment approaches Company expects to deliver two or more clinical candidates by the end of 2025 and plans to initiate at least two new Phase 1 studies by the end of 2026 Cash runway extended into 2028 through combination of new licensing agreement with GSK, reduced operating expenses and enhanced financial discipline TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 3, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced a significant strategic restructuring to focus its resources on high-value mRNA projects in oncology and other select areas of substantial unmet medical need.
FAQ
- What is the primary business of CureVac NV?
- What is the ticker symbol for CureVac NV?
- Does CureVac NV pay dividends?
- What sector is CureVac NV in?
- What industry is CureVac NV in?
- What country is CureVac NV based in?
- When did CureVac NV go public?
- Is CureVac NV in the S&P 500?
- Is CureVac NV in the NASDAQ 100?
- Is CureVac NV in the Dow Jones?
- When was CureVac NV's last earnings report?
- When does CureVac NV report earnings?